Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by PFG Investments LLC

PFG Investments LLC cut its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 19.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,425 shares of the biotechnology company’s stock after selling 600 shares during the period. PFG Investments LLC’s holdings in Axon Enterprise were worth $626,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in AXON. Westfield Capital Management Co. LP lifted its position in Axon Enterprise by 184.3% during the third quarter. Westfield Capital Management Co. LP now owns 696,193 shares of the biotechnology company’s stock valued at $138,535,000 after buying an additional 451,350 shares in the last quarter. BKM Wealth Management LLC acquired a new stake in Axon Enterprise in the 4th quarter valued at $32,000. Sumitomo Mitsui Trust Holdings Inc. raised its position in Axon Enterprise by 0.3% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 147,345 shares of the biotechnology company’s stock valued at $29,320,000 after purchasing an additional 495 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in shares of Axon Enterprise by 11.5% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 63,778 shares of the biotechnology company’s stock worth $12,691,000 after purchasing an additional 6,585 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its position in shares of Axon Enterprise by 10.1% in the third quarter. Ameriprise Financial Inc. now owns 379,286 shares of the biotechnology company’s stock worth $75,474,000 after buying an additional 34,728 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, President Joshua Isner sold 35,400 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $251.68, for a total transaction of $8,909,472.00. Following the sale, the president now owns 309,564 shares in the company, valued at approximately $77,911,067.52. The transaction was disclosed in a filing with the SEC, which is available through this link. 6.10% of the stock is currently owned by corporate insiders.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $315.64 on Thursday. Axon Enterprise, Inc. has a 12 month low of $175.37 and a 12 month high of $325.63. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.00 and a quick ratio of 2.66. The stock’s 50 day moving average price is $283.44 and its 200 day moving average price is $245.70. The stock has a market cap of $23.82 billion, a price-to-earnings ratio of 137.24 and a beta of 0.93.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.29. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. The business had revenue of $432.14 million for the quarter, compared to the consensus estimate of $418.97 million. Equities research analysts anticipate that Axon Enterprise, Inc. will post 2.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on AXON. Robert W. Baird upped their price objective on shares of Axon Enterprise from $260.00 to $300.00 and gave the company an “outperform” rating in a research report on Thursday, February 22nd. Barclays lifted their price objective on Axon Enterprise from $296.00 to $308.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. The Goldman Sachs Group lifted their price target on shares of Axon Enterprise from $297.00 to $339.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. JPMorgan Chase & Co. increased their price objective on shares of Axon Enterprise from $285.00 to $330.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 28th. Finally, StockNews.com downgraded Axon Enterprise from a “buy” rating to a “hold” rating in a research note on Thursday, March 14th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $301.73.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.